Chronic graft versus host diseaseNews & Research
15 curated articles for Chronic graft versus host disease — FDA updates, peer-reviewed research, clinical-trial milestones, and sponsor press releases. Sorted newest-first.
- Expert opinion on biological therapy Apr 22, 2026
Emerging strategies for the prevention and management of chronic graft-versus-host disease.
Chronic graft-versus-host disease remains a major cause of late morbidity and mortality after allogeneic hematopoietic stem cell transplantation. Conventional prevention and management strategies, heavily reliant on prolonged immunosuppression, are limited by suboptimal efficacy, substantial toxicit...
Why it matters: Recent peer-reviewed research on Chronic graft versus host disease that may be relevant for patients and caregivers.
- Stem cell reviews and reports Apr 20, 2026
Evolving Paradigms in Chronic Graft-Versus-Host Disease: From Global Immunosuppression to Precision Targeted and Cell-Based Therapies.
Evolving Paradigms in Chronic Graft-Versus-Host Disease: From Global Immunosuppression to Precision Targeted and Cell-Based Therapies.
Why it matters: Recent peer-reviewed research on Chronic graft versus host disease that may be relevant for patients and caregivers.
- Transplantation and cellular therapy Apr 8, 2026
Toward Better and More Effective Clinical Trials for Chronic Graft-Versus-Host Disease.
While the incidence of chronic Graft-versus-Host Disease (chronic GVHD) is declining due to advances in prophylaxis and survival is improving due to better supportive care, first-line treatment of chronic GVHD continues to be based on corticosteroids. Numerous attempts to establish more effective or...
Why it matters: Recent peer-reviewed research on Chronic graft versus host disease that may be relevant for patients and caregivers.
- Transplantation and cellular therapy Apr 8, 2026
Belumosudil for Chronic Graft-Versus-Host Disease: A Systematic Review and Meta-Analysis.
Chronic graft-versus-host disease (cGvHD) is a debilitating complication following allogeneic hematopoietic stem cell transplantation, often refractory to standard therapies. Belumosudil, a selective ROCK2 inhibitor with immunomodulatory and antifibrotic properties, has emerged as a targeted treatme...
Why it matters: Recent peer-reviewed research on Chronic graft versus host disease that may be relevant for patients and caregivers.
- Arthritis & rheumatology (Hoboken, N.J.) Apr 7, 2026
Linezolid-mediated Prevention of Fibroblast Activation and Tissue Fibrosis via Mitochondrial Translation Inhibition.
Beyond its role as a ribosome-targeting antibiotic, linezolid was recently shown to modulate immune responses by inhibiting mitochondrial translation. Because mitochondrial dysfunction is implicated in various fibrotic diseases, including systemic sclerosis (SSc), this study aimed to evaluate the an...
Why it matters: Recent peer-reviewed research on Chronic graft versus host disease that may be relevant for patients and caregivers.
- Bone marrow transplantation Apr 7, 2026
Chronic graft-versus-host disease: Current situation and unmet needs - A European position statement.
Chronic graft-versus-host disease (cGVHD) remains the leading cause of late morbidity and non-relapse mortality after allogeneic hematopoietic cell transplantation, despite major advances in transplant techniques and supportive care. This European position statement provides a comprehensive and forw...
Why it matters: Recent peer-reviewed research on Chronic graft versus host disease that may be relevant for patients and caregivers.
- Nature communications Apr 1, 2026
Stem-like memory-T maintenance and differentiation into tissue-resident T cells sustain chronic graft-versus-host disease in mice.
Pathogenic CD4 + memory T cells (Tm) sustain chronic inflammation, but mechanisms remain undefined. Here, we identify four donor-type CD4 + Tm subsets in the target tissues of autoimmune-like chronic graft-versus-host disease in mice: Ly108 + CD69 - stem-like memory T cells (Tsm), Ly108 + CD69 + res...
Why it matters: Recent peer-reviewed research on Chronic graft versus host disease that may be relevant for patients and caregivers.
- Biomolecules Mar 28, 2026
Alpha 1 Antitrypsin Suppresses Autoantibody Production and Cellular Autoimmunity in Chronic Graft-Versus-Host Disease (cGVHD) in a Lupus Mouse Model.
Systemic lupus erythematosus (SLE) is a severe autoimmune disease that is challenging to treat due to poor understanding of its pathogenesis and etiology. Clearly understanding and dissecting the therapeutic effects of potential treatment in animal models are important. It has been shown that human ...
Why it matters: Recent peer-reviewed research on Chronic graft versus host disease that may be relevant for patients and caregivers.
- Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi Mar 16, 2026
[Efficacy and safety of basiliximab in gastrointestinal chronic graft-versus-host disease].
Objective: To explore the efficacy and safety of basiliximab for gastrointestinal (GI) chronic graft-versus-host disease (cGVHD) . Methods: This was a retrospective case series. Patients who developed GI-cGVHD after transplantation at the Peking University Institute of Hematology between January 1, ...
Why it matters: Recent peer-reviewed research on Chronic graft versus host disease that may be relevant for patients and caregivers.
- Blood Mar 7, 2026
BET inhibition blunts antibody production and macrophage-mediated fibrosis to restore lung function in murine cGVHD.
Chronic graft-versus-host disease (cGVHD) significantly contributes to late mortality after allogeneic stem cell transplantation, with bronchiolitis obliterans syndrome (BOS) being a particularly lethal and treatment-resistant complication despite available therapies. Bromodomain and Extra terminal ...
Why it matters: Recent peer-reviewed research on Chronic graft versus host disease that may be relevant for patients and caregivers.
- Stem cell reviews and reports Mar 6, 2026
Optimal Treatment of Steroid-refractory Chronic Graft-versus-host Disease (cGvHD) in the Era of Novel drugs - a Systematic Review and Meta-analysis.
Despite recent novel drug approvals and numerous treatment options, the steroid-refractory chronic graft-versus-host disease (SR-cGvHD) remains a significant clinical problem. We aimed to evaluate the efficacy and safety of available therapies in adult patients, based on a systematic review and meta...
Why it matters: Recent peer-reviewed research on Chronic graft versus host disease that may be relevant for patients and caregivers.
- International journal of hematology Feb 13, 2026
Recent advances in the pathophysiology of acute and chronic graft-versus-host disease.
Acute and chronic graft-versus-host disease (GVHD) remains major obstacles to the success of allogeneic hematopoietic cell transplantation (allo-HCT). Recent advances in experimental models and clinical studies have refined our understanding of the cellular and molecular mechanisms that drive GVHD a...
Why it matters: Recent peer-reviewed research on Chronic graft versus host disease that may be relevant for patients and caregivers.
- Haematologica Feb 2, 2026
Dental plaque microbiota following allogeneic hematopoietic cell transplantation and risk of chronic graft- versus -host disease.
Microbiota disruptions have been associated with short-term complications after allogeneic hematopoietic cell transplantation (alloHCT). However, only a few studies have examined the relationship between dysbiosis and chronic graft-versus-host disease (cGvHD), the main long-term immunologic toxicity...
Why it matters: Recent peer-reviewed research on Chronic graft versus host disease that may be relevant for patients and caregivers.
- Transplantation and cellular therapy Feb 1, 2026
Obesity Associations with Chronic Graft-Versus-Host Disease.
Obesity is increasing in prevalence and has been linked to inflammation, leading to worse outcomes in various disease states. Preclinical studies have demonstrated deleterious effects of obesity on graft-versus-host disease (GVHD). Several retrospective clinical studies have investigated the impact ...
Why it matters: Recent peer-reviewed research on Chronic graft versus host disease that may be relevant for patients and caregivers.
- Transplantation and cellular therapy Feb 1, 2026
Effect of Inflammatory Bowel Disease on Clinical Outcomes of Hematopoietic Cell Transplantation for Inborn Errors of Immunity.
Inflammatory bowel disease (IBD) is a phenotype of patients with inborn errors of immunity (IEI). Allogeneic hematopoietic cell transplantation (HCT) is an established curative treatment for IEI; however, the effect of IBD on HCT outcomes is unclear. We evaluated the impact of IBD on post-HCT progno...
Why it matters: Recent peer-reviewed research on Chronic graft versus host disease that may be relevant for patients and caregivers.
More on Chronic graft versus host disease
Articles aggregated from peer-reviewed journals (PubMed), sponsor press releases, SEC 8-K filings, and FDA announcements. Original-source links are preserved on each article page. Editorial tags (Breaking / Notable / Update) reflect UniteRare's curation-time priority assessment.